Updating the WHO target product profile for next-generation Mycobacterium tuberculosis drug susceptibility testing at peripheral centres
Open Access
- 31 March 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (3), e0001754
- https://doi.org/10.1371/journal.pgph.0001754
Abstract
There were approximately 10 million tuberculosis (TB) cases in 2020, of which 500,000 were drug-resistant. Only one third of drug-resistant TB cases were diagnosed and enrolled on appropriate treatment, an issue partly driven by a lack of rapid, accurate drug-susceptibility testing (DST) tools deployable in peripheral settings. In 2014, World Health Organization (WHO) published target product profiles (TPPs) which detailed minimal and optimal criteria to address high-priority TB diagnostic needs, including DST. Since then, the TB community’s needs have evolved; new treatment regimens, changes in TB definitions, further emergence of drug resistance, technological advances, and changing end-users requirements have necessitated an update. The DST TPP’s revision was therefore undertaken by WHO with the Stop TB Partnership New Diagnostics Working Group. We describe the process of updating the TPP for next-generation TB DST for use at peripheral centres, highlight key updates, and discuss guidance regarding technical and operational specifications.Keywords
Funding Information
- United States Agency for International Development (Grant Recipient: WHO Global TB Programme and the New Diagnostics Working Group of the Stop TB Partnership)
- Wellcome Trust (214560/Z/18/Z)
This publication has 25 references indexed in Scilit:
- Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challengesGenome Medicine, 2019
- Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issuesNature Reviews Microbiology, 2019
- A systematic review of biomarkers to detect active tuberculosisNature Microbiology, 2019
- Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapiesThe Lancet Infectious Diseases, 2018
- The Tuberculosis Cascade of Care in India’s Public Sector: A Systematic Review and Meta-analysisPLoS Medicine, 2016
- Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance projectThe Lancet Infectious Diseases, 2016
- Tuberculosis Diagnostics in 2015: Landscape, Priorities, Needs, and ProspectsThe Journal of Infectious Diseases, 2015
- Tuberculosis diagnostics: which target product profiles should be prioritised?European Respiratory Journal, 2014
- Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trialThe Lancet, 2014
- Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes.1969